智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and Company）将收购该公司旗下的FXR项目及主打疗法FXR314。FXR314是一款潜在“best-in-class ...

Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development and will be responsible for all future clinical development. Organovo is a ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...